Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for Painful Chronic Pancreatitis
NCT06426160Phase 2Active, not recruiting
- Start
- May 2024
- Primary completion
- Oct 2026
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic pancreatitis (CP) comparing Tocilizumab with Placebo (2 arms). Primary endpoint: Comprehensive Pain Assessment Tool Short Form. Started May 2024; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
chronic pancreatitis (CP)
Beyond the preview
Go deeper on NCT06426160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06426160.